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Abstract: A number of epidemiological and clinical studies have demonstrated that plasma 
high-density lipoprotein (HDL) level is a strong inverse predictor of cardiovascular events. HDL 
is believed to retard the formation of atherosclerotic lesions by removing excess cholesterol 
from cells and preventing endothelial dysfunction. Lecithin cholesterol acyltransferase (LCAT) 
plays a central role in the formation and maturation of HDL, and in the intravascular stage of 
reverse cholesterol transport: a major mechanism by which HDL modulates the development 
and progression of atherosclerosis. A defect in LCAT function would be expected to enhance 
atherosclerosis, by interfering with the reverse cholesterol transport step. As such, one would 
expect to find more atherosclerosis and cardiovascular events in LCAT-deficient patients. But 
this relationship is not always evident. In this review, we describe contradictory reports in the 
literature about cardiovascular risks in this patient population. We discuss the paradoxical find-
ing of severe HDL deficiency and an absence of subclinical atherosclerosis in LCAT-deficient 
patients, which has been used to reject the hypothesis that HDL level is important in the pro-
tection against atherosclerosis. Furthermore, to illustrate this paradoxical finding, we present a 
case study of one patient, referred for evaluation of global cardiovascular risk in the presence 
of a low HDL cholesterol level, who was diagnosed with LCAT gene mutations.
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Introduction
Several studies have demonstrated an inverse correlation between plasma high-density 
lipoprotein (HDL) and the risk of coronary artery disease, and have concluded that 
HDL is a powerful predictor of the disease.1,2
Mutations in lecithin-cholesterol acyltransferase (LCAT), apolipoprotein A-1 
(ApoA-1), and ATP binding cassette A1 have been shown to underlie familial hypoal-
phalipoproteinemia, whereas cholesteryl ester transfer protein (CETP) gene defects 
underlie familial hyperalphalipoproteinemia. Homozygous mutations in the LCAT 
gene cause LCAT deficiency – a very rare metabolic disorder with two hypoalphali-
poproteinemia syndromes: (1) familial LCAT deficiency (FLD), characterized by a 
complete lack of enzyme activity, and (2) “fish eye disease” (FED), characterized by 
a partially defective enzyme. It has been suggested that LCAT exhibits two activi-
ties in normal plasma: (1) alpha-LCAT activity, specific for lipoproteins that migrate 
with alpha mobility upon gel electrophoresis, and (2) beta-LCAT activity, which is 
specific for pre-beta, and beta-migrating lipoprotein (very-low-density lipoprotein 
[VLDL] and LDL).
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FED is classified as an alpha-LCAT deficiency, whereas 
FLD has been proposed to result from a lack of both alpha- 
and beta-LCAT activity. Alpha- and beta-LCAT activity 
represents two functional aspects of the same protein.
LCAT plays a central role in the formation and 
maturation of HDL, and in the intravascular stage of 
reverse cholesterol transport, a major mechanism by 
which HDL modulates the development and progression 
of   atherosclerosis. Deficiency in LCAT is characterized 
by a deficit in the esterification of plasma cholesterol. 
A defect in LCAT function would be expected to enhance 
atherosclerosis, by interfering with the reverse cholesterol 
transport step. But there have been contradictory reports 
regarding this in the literature.3–6
HDL and LCAT biochemistry  
and physiology
The human LCAT gene, localized at 16q22, is primarily 
expressed in the liver, but is also produced in smaller amounts 
in the brain and testes.5 LCAT is a 416-amino acid-long pro-
tein that circulates in the blood, either bound to lipoproteins 
or in lipid-free form. ApoA-1 is the principal physiological 
activator of LCAT.4
The LCAT reaction occurs in two steps. After binding to 
a lipoprotein, LCAT cleaves the fatty acid in the sn-2 position 
of phosphatidylcholine and transfers it onto a serine residue. 
Next, the fatty acid is transesterified to the 3-β-hydroxyl 
group on the A-ring of cholesterol, to form cholesterol ester 
(Figure 1). Since cholesterol ester is more hydrophobic than 
free cholesterol, it migrates into the hydrophobic core of 
lipoprotein particles. Approximately 75% of plasma LCAT 
activity is associated with HDL. But LCAT is also able to 
bind and produce cholesteryl ester on LDL and other ApoB-
containing lipoproteins.5
LCAT has been shown to promote the efflux of choles-
terol from peripheral cells3 (Figure 1). The esterification of 
cholesterol on HDL increases the concentration gradient 
from free cholesterol between cell membranes and HDL. 
The esterification of cholesterol transforms the discoidal-
shaped nascent HDL, with a pre-β migration position on 
agarose gels, into spherical-shaped HDL, termed α-HDL. 
As cholesteryl esters are much more hydrophobic than cho-
lesterol, another consequence of LCAT is that it prevents 
the spontaneous back-exchange of cholesterol from HDL to 
cells, and thus promotes net cellular removal of cholesterol.3 
Cholesteryl esters on HDL and LDL are essentially trapped 
on these lipoproteins, until they can be removed from the 
circulation by the liver.5
Without ongoing esterification of cholesterol, the capac-
ity of HDL to remove and bind additional cholesterol would 
eventually be diminished. CETP may further enhance this 
process by transferring cholesteryl esters formed by LCAT 
from HDL onto LDL, creating additional capacity for HDL 
to bind cholesterol.
LCAT deficiency: epidemiology  
and clinical presentation
LCAT deficiency is a rare disease. Thirty families have been 
described in the literature; the prevalence is below 1/1,000,000; 
only sporadic cases have been reported. The disease is 
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Figure 1 High-density lipoprotein metabolism.
Abbreviations: PC, phosphatidylcholine; lysoPC, lysophosphatidylcholine; LPL, lipoprotein lipase; EC, esterified cholesterol; A-1, apo-A1.
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  transmitted as an autosomal recessive trait. LCAT   deficiency 
results in two clinical entities: (1) FLD – complete 
LCAT deficiency – in which the lack of activity of the enzyme 
affects both the esterification on HDL (α-LCAT activity) 
and LDL (β-LCAT activity), and (2) FED – partial LCAT 
deficiency – in which only α-LCAT activity is impaired.7,8 
In both cases, there is decreased plasma HDL (,10% of 
normal level) and the presence of corneal opacities, due to 
cholesterol deposits in the cornea, which begin most often 
in childhood, affecting the peripheral cornea before reaching 
the center. These anomalies are the only elements found in 
FED and, in some cases, may require a corneal transplant. 
Patients with FLD may also manifest hypertriglyceridemia, 
normochromic hemolytic anemia, and proteinuria. In this 
form, the prognosis depends mainly on the evolution of renal 
function (due to abnormal deposition of lipoprotein, leading 
to kidney failure).
LCAT deficiency and atherosclerosis
HDL cholesterol level is a strong inverse predictor of cardio-
vascular events. HDL is believed to retard the formation of 
atherosclerotic lesions by removing excess cholesterol from 
cells and preventing endothelial dysfunction.9,10
LCAT deficiency is a metabolic disorder characterized by 
very low HDL levels. Theoretically, hypoalphalipoproteine-
mia patients with LCAT deficiency should be at increased 
cardiovascular risk due to their HDL deficiency and defective 
reverse cholesterol transport. Thus, it would be expected that 
more atherosclerosis and cardiovascular events would be 
detected in LCAT-deficient patients. However, this relation-
ship is not always evident. Previous studies have reported 
conflicting findings about potential increased cardiovascular 
risks in this patient population.
Early cross-sectional studies reported both decreased and 
increased LCAT activity in patients with angiographically-
confirmed coronary artery disease.11,12
Some studies have reported increased atherosclerosis in 
patients with LCAT deficiency. Hovingh et al demonstrated 
that patients who are heterozygous for LCAT mutations have 
increased atherosclerosis, compared with familial controls.13 
This was illustrated by the fact that 47 heterozygotes for 
the LCAT gene mutation presented with a thicker intimal 
medial thickness (IMT) than 58 family members, as controls 
(0.623 mm versus 0.591 mm, respectively; P , 0.0015, 
adjusted for age, sex, and alcohol), and a 2.1-fold increase 
in high-sensitivity C-reactive protein (hsCRP) levels 
(4.40 mg/L versus 2.0 mg/L, respectively; P , 0.0001). 
Compared with family controls, heterozygotes exhibited a 
mean 36% decrease in HDL levels (0.812 ± 0.238 mmol/L 
versus 1.276 ± 0.387 mmol/L), and a mean decrease of 22% 
in ApoA-1 levels (1.21 ± 0.16 g/L versus 1.56 ± 0.28 g/L; 
P , 0.0001). Given the small number of study subjects, 
cardiovascular events were not compared.13
In another study, LCAT-deficient patients had not only a 
reduced HDL level but also a marked increase in both hsCRP 
and IMT.6 The study investigated 68 carriers of LCAT gene 
mutations, with an HDL level of 0.70 ± 0.32 mmol/L, and 74 
family controls, with an HDL level of 1.59 ± 0.57 mmol/L. 
Carriers of LCAT gene mutations displayed a significant, 
twofold increase in median hsCRP levels, compared with 
controls. IMT progression in heterozygotes was 0.00538 mm/
year, versus 0.00301 mm/year in controls (P , 0.0001).6
It is worth noting that the reported increase of athero-
sclerosis in LCAT-deficient patients was based on hsCRP 
levels – a controversial cardiovascular marker – and IMT, 
with values in LCAT carriers within a “normal” range. 
Given these data, even if LCAT deficient patients have an 
increase cardiovascular risk, this increased risk appears to 
be minimal.
In a larger study, Calabresi et al did not find evidence for 
subclinical atherosclerosis in patients with LCAT   deficiency.8 
They investigated a total of 120 patients: 40 carriers of LCAT 
gene mutations and 80 matched blood donor controls. Age, 
body mass index (BMI), blood glucose, and smoking status 
were comparable between the two groups. HDL levels were 
low in carriers (0.772 ± 0.446 mmol/L) versus   controls 
(1.497 ± 0.307 mmol/L) (P , 0.0001). Maximum and   average 
IMT values were significantly lower in carriers than in con-
trols, even after adjustment for age, sex, BMI, smoking status, 
and blood pressure. Low HDL levels in the carriers of LCAT 
gene mutations did not result in   subclinical   atherosclerosis. 
Indeed, these authors found that the   inheritance of a mutated 
LCAT genotype had a remarkable gene- and dose-dependent 
effect on reducing carotid IMT.8
In a Canadian study, two homozygote and seven heterozy-
gote patients with FLD, aged up to 70 years, were followed 
for 25 years, during which time none of the patients suffered 
any vascular events. The IMT in homozygote patients did not 
progress over the last four years of the study, and they were 
shown to have normal endothelial function (as measured by 
flow-mediated dilation of the brachial artery).14
These seemingly contradictory results may potentially be 
explained by the fact that most of these studies were relatively 
small, and did not examine other important proteins and 
enzymes of the reverse cholesterol transport pathway, which 
can potentially alter the effect of LCAT on atherosclerosis. 
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Furthermore, individuals with LCAT mutations have very 
few clinical events, for a small number of patients.
Clinical case
To further illustrate the paradoxical relationship between 
LCAT deficiency, very low HDL levels, and cardiovascular 
risk factors, we report one patient, referred for evaluation 
of global cardiovascular risk in the presence of a low 
HDL level.
A 52 year-old women presented with no significant 
familial or past medical history, other than an ophthalmologic 
anomaly with corneal opacity but normal vision. The 
patient had no cardiovascular symptoms, a normal 
clinical examination, and a normal ECG. Risk factors 
and atherosclerosis burden are reported in Table 1. 
Standard anthropometric measures, blood analyses, and 
atherosclerosis markers were obtained, as previously 
reported.15,16 The patient’s HDL level was significantly lower 
than the level typically reported for carriers (0.15 mmol/L) 
Cardiovascular evaluation found no trace of subclinical 
atherosclerosis (IMT, carotid plaques, ankle brachial index, 
and stress test), or associated risk factors such as hsCRP. 
Genetic analysis identified two mutations, heterozygous on 
the LCAT gene: (1) Exon 3, c.321C . A, Tyr83Stp, and 
(2) Exon 3 c.367C . T, Arg99cys. These two mutations have 
been previously described in one other patient (with similar 
findings: very low HDL and no cardiovascular disease). It 
was not possible to complete a family history of this patient, 
as she did not know her family.
The paradoxical finding of severe HDL deficiency and 
the reported absence of subclinical atherosclerosis in LCAT-
deficient patients has been used to reject the hypothesis 
that HDL is important in protection against atherosclerosis. 
Potential mechanisms to explain these findings have been 
postulated, such as preferential clearance of HDL fractions 
that have less atherogenic potential.17 Decreased LDL and 
ApoB levels have also been suggested as potential explana-
tions for the lack of marked cardiovascular disease. However, 
there is no clear evidence that LDL levels in these patients 
are decreased.8 A recent report demonstrated that the capacity 
of HDL to accept cholesterol from macrophages (cholesterol 
efflux capacity – a metric of HDL function) has a strong 
inverse association with both carotid IMT and the likeli-
hood of angiographic coronary artery disease, independent 
of HDL level.18
These current insights into LCAT disorders further add 
to our understanding of the variable relationship between 
HDL metabolism and atherosclerosis risk.
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